Abstract: The aim of this study is to investigate the clinical efficacy of dendritic cell and cytokine-induced killer cell（DC-CIK） immunotherapy in combination with chemotherapy in the treatment of hematological malignancies. This study collected eligible randomized controlled studies published from January 2000 to February 2023 from databases such as PubMed, Web of Science, The Cochrane Library, Embase, CNKI, WanFang Data, SinoMed and VIP database respectively by the same method, and applied RevMan 5.4.1 software for Meta-analysis. A total of 15 papers related to 894 patients, wherein 686 myeloma patients and 208 leukemia patients. There were 451 patients in the DC-CIK combined with chemotherapy treatment group were set as combination therapy group, while a total of 443 patients in the chemotherapy treatment group were set as the chemotherapy（control） group. The analysis results showed that the combination treatment group was better than the chemotherapy group in terms of clinical efficacy, prognosis, survival quality and various immune indexes（T lymphocyte subpopulation distribution and cytokine secretion level）, and did not cause specific side effects to patients. This study demonstrates that DC-CIK immunotherapy combined with chemotherapy can significantly improve the clinical efficacy of patients with malignant hematological tumors, improve their immune function and enhance the anti-tumor ability of the body.